| Date Filed | Type | Description |
| 08/11/2023 |
10-Q/A
| Quarterly Report for the period ended June 30, 2023 [amend] |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 06/28/2023 |
8-K
| Other Events Interactive Data |
| 06/09/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/09/2023 |
4
| Blischak Matthew P. (CEO) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Granted 962,899 options to buy
@ $0.285, valued at
$274.4k
|
|
| 06/09/2023 |
4
| Lange Christian H. (Director) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Granted 10,000 options to buy
@ $0.285, valued at
$2.9k
|
|
| 06/09/2023 |
4
| SMISEK JEFFERY A (Director) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Granted 10,000 options to buy
@ $0.285, valued at
$2.9k
|
|
| 06/09/2023 |
4
| Haft Nicholas (Director) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Granted 10,000 options to buy
@ $0.285, valued at
$2.9k
|
|
| 06/09/2023 |
4
| FERRANTE DOMENIC J (Director) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Granted 10,000 options to buy
@ $0.285, valued at
$2.9k
|
|
| 06/09/2023 |
4
| Graf Susan E (Director) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Bought 5,010 shares
@ $0.27, valued at
$1.4k
Granted 10,000 options to buy
@ $0.285, valued at
$2.9k
|
|
| 06/09/2023 |
4
| Shumway Chris (10% Owner) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Granted 10,000 options to buy
@ $0.285, valued at
$2.9k
|
|
| 05/18/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/16/2023 |
3
| Blischak Matthew P. (CEO) has filed a Form 3 on Finch Therapeutics Group, Inc. |
| 05/16/2023 |
3
| THIBAULT LANCE E (CFO) has filed a Form 3 on Finch Therapeutics Group, Inc. |
| 05/11/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/11/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/23/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/23/2023 |
4
| Blaustein Marc (COO) has filed a Form 4 on Finch Therapeutics Group, Inc.|
Txns:
| Sold 4,619 shares
@ $0.38, valued at
$1.8k
|
|
| 01/26/2023 |
8-K
| Termination of a Material Definitive Agreement Interactive Data |
| 01/24/2023 |
8-K
| Quarterly results |
| 01/06/2023 |
8-K
| Quarterly results |
| 12/12/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/14/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
|